Vascular calcification in chronic kidney disease;La calcificazione vascolare nel paziente con insufficienza renale cronica

Recenti Progressi in Medicina

Volumn 101, Issue 11, 2010, Pages 442-452

  Cozzolino, Mario ^a   Missaglia, Elena ^a   Ortiz, Alberto ^b   Bellasi, Antonio ^c   Adragao, Teresa ^d   Apostolou, Theofanis ^e   Vescovo, Giorgio ^f   Gallieni, Maurizio ^g  

^a SAN PAOLO HOSPITAL   (Italy)

^b OspedaleVirgen del Rocío ^*  (Spain)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Ospedale S Cruz   (Portugal)

^e Ospedale Evangelismos   (Greece)

^f Ospedale di Vicenza   (Italy)

^g SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Calcium; Cardiovascular risk; Chronic kidney disease; Fibroblast growth factor 23; Hyperparathyroidism; Hyperphosphatemia; Parathyroid hormone; Sevelamer; Vascular calcification

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; PHOSPHATE BINDING AGENT;

ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; HUMAN; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE;

ARRHYTHMIAS, CARDIAC; BONE DISEASES, METABOLIC; CALCINOSIS; CALCIUM; CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY DISEASES; PHOSPHORUS; VASCULAR DISEASES;

EID: 78751629718     PISSN: 00341193     EISSN: 20381840     Source Type: Journal    
DOI: 10.1701/526.6287     Document Type: Article

References (75)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kideny Dis 1998; 32 (Suppl 3): S112-S9.
2. Moe S, Drüeke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-53.
3. KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76 (suppl 113): S1-S130.
4. Chi-yuan Hsu. FGF-23 and outcomes research: when physiology meets epidemiology. New Engl J Med 2008; 359: 584: 92.
5. Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009; 20: 164-71.
6. Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: The Heart And Soul Study. Nephrol Dial Transplant 2010; 25: 993-7.
7. Kanbay M, Goldsmith D, Akcay A, Covic A. Phosphate: the silent stealthy cardiorenal culprit in all stages of chronic kidney disease. Blood Purif 2009; 27: 220-30.
8. Mirza MA, Larsson A, Lind L, et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-90.
9. Onufrak SJ, Bellasi A, Shaw LJ, et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 2008; 199: 424-31.
10. Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404.
11. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358: 1336-45.
12. Watanabe E, Lemos MM, Manfredi SR, Draibe SA, Canziani ME. Impact of cardiovascular calcification in nondialyzed patients after 24 months of followup. Clin J Am Soc Nephrol 2010; 5: 189-94.
13. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-41.
14. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388-96.
15. Silver J, Kilav R, Naveh-Many T, et al. Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002; 283: 367-76.
16. Cozzolino M, Dusso AS, Liapis H, et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002; 13: 2299-308.
17. Adeney K, Siscovick D, Ix J, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-7.
18. Mathew S, Lund R, Chaudhary L, Geurs T, Hruska K. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2009; 19: 1509-19.
19. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-36.
20. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003; 64: 1653-61.
21. Dhingra, R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-85.
22. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-33.
23. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-8.
24. Voormolen N, Noordzij M, Grootendorst DC, et al. PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-16. Epub 2007.
25. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-87.
26. Liu S, Guo R, Simpson LG, et al. Regulation of FGF23 expression but not degradation by Phex. J Biol Chem 2003; 278: 37419-26.
27. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 infibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112: 683:92.
28. Fukumoto S. Physiological regulation and disordersof phosphate metabolism: pivotal role of fibroblast growth factor 23. Intern Med 2008; 47: 337-43.
29. Saito T, Fukumoto S. Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. Int J Pediatr Endocrinol 2009; 2009: 496514. Epub 2009.
30. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth-factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidneydisease. J Am Soc Nephrol 2005; 16: 2205-15.
31. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-52.
32. Westerberg PA, Linde T, Wikstrom B, et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3202-7.
33. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-8. (Pubitemid 41623344)
34. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild To Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-8.
35. Mirza M, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009; 24: 3125-31.
36. Mirza M, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-51.
37. Nasrallah M, Amal R, El-Shehaby AR, et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 2679-85.
38. Jean G, Bresson E, Terrat JC, et al. Peripheralvascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-55.
39. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2009.
40. Nagano N, Miyata S, Abe M, et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69: 531-7.
41. Koiwa F, Onoda N, Kato H, et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysispatients in Japan. Ther Apher Dial 2005; 9: 340-6.
42. Oliveira R, Cancela A, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-91.
43. Nordin B. The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women. Osteoporos Int 2009; 20: 2135-43.
44. Feskanich D, Willett WC, Colditz GA. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr 2003; 77: 504-11.
45. Jackson R, LaCroix A, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-83. (Pubitemid 43247138)
46. Reid IR, Grey AB, Bolland BJ. Calcium supplementation for older men and women? Osteoporos Int 2008; 19: 1119-23.
47. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-8.
48. Block GA, Zeig S, Sugihara J, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008; 23: 2311-8.
49. Schaub MC, Martin A, Hefti MA, Zaugg M. Integration of calcium with the signaling network in cardiac myocytes. J Mol Cell Cardiol 2006; 41: 183-214.
50. Chen X, Zhang X, Kubo H, et al. Ca2+ influx-induced sarcoplasmic reticulum ca2+ overload causes mitochondrial-dependent apoptosis in ventricular myocytes. Circ Res 2005; 97: 1009-17.
51. Harding SE, MacLeod KT, Jones SM, Vescovo G, Poole-Wilson PA. Contractile responses of myocytes isolated from patients with cardiomyopathy. Eur Heart J 1991; 12 (Suppl. D): 44-8.
52. Abriel HSJ, Keller DI, Gavillet B, et al. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss Med Wkly 2004; 134: 685-94.
53. Choi BR, Burton F, Salama G. Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome. J Physiol 2002; 543: 615-31.
54. Kögler H, Schott P, Toischer K, et al. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ AT-Pase expression. Circulation 2006; 113: 2724-32.
55. Wollert KC, Yurukova S, Kilic A, et al. Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I. Br J Pharmacol 2003; 140: 1227-36.
56. Kögler H, Schott P, Toischer K, et al. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ AT-Pase expression. Circulation 2006; 113: 2724-32.
57. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997; 132: 245-50.
58. Adragao T, Pires A, Lucas C, et al. Asimple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1480-8.
59. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-40.
60. Okuno S, Ishimura E, Kitatani K, et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 2007; 49: 417-25.
61. Ogawa T, Ishida H, Akamatsu M, et al. Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients. Int Urol Nephrol 2010; 42: 187-94.
62. Schlieper G, Kruger T, Djuric Z, et al. Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int 2008; 74: 1582-7.
63. Adragao T, Pires A, Curto JD, et al. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant 2009; 24: 997-1002.
64. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, et al. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 239-46.
65. Adragao T, Branco P, Birne R, et al. Bone mineral density, vascular calcifications, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2009; 28: 668-72.
66. Adragao T, Herberth J, Monier-Faugere MC, et al. Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients. Osteoporos Int 2010; 21: 619-25.
67. Combe C, Albert JM, Bragg-Gresham JL, et al. The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2009; 54: 680-92.
68. De Solis A, Gonzales-Pacheco FR, Deudero JJ, et al. Alkalinization potentiates vascular calcium deposition in an uremic milieu. J Nephrol 2009; 22: 647-53.
69. Román-García P, Carrillo-López N, Fernández-Martín JL, Naves-Díaz M, Ruiz-Torres MP, Cannata-An-día JB. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121-8.
70. Cannata-Andía JB, Rodríguez-García M, Carrillo-López N, et al. Vascular calcifications: pathogenesis, management and impact on clinical outcomes. J Am Soc Nephrol 2006; 17 (Suppl 3): S267-73.
71. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008; 336: 262-6.
72. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764-72.
73. Borzecki A, Lee A, Wang SW, Brenner L, Kazis LE. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther 2007; 32: 617-24.
74. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-24.
75. Suki WN, Zabenh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-7.